Transforming data into better healthcare. Winter 2012By Dr Jens Hoefkens The healthcare industry is drowning in data for which it lacks established data analysis processes. This situation exists despite the fact that appropriate and efficient data analysis pro...
|
Saved by the BEL: ringing in a common language for the life sciences. Fall 12By Ted Slater and Dr Diane H. Song Established fields of study preserve their history and support advancement by developing and using a common language, without which those fields could not progress at a reasonable pace. T...
|
Biological analysis and interpretation for improved research outcomes. Spring 12By Dr Douglas Bassett In the last few years, technological advancements in the life sciences have
changed many ways in which we think about research. Next-generation sequencing, qPCR and microRNA offer n... |
The Information Symphony: data orchestration for a changing industry managing data on a platform for innovation. Spring 12By Chris Molloy A leading ballet conductor1 recently told me of courses which he runs for senior business leaders. He allows them to conduct an orchestra: first, very strictly, with close direction appli...
|
Simultaneous visualisation of attrition and timelines: funnel diagrams. Winter 11By Dr Linda Hirons, Dr Craig Johnstone and Colin Sambrook-Smith In drug discovery both attrition and timelines are important factors to consider when applying process improvement to lead optimisation. In our attempts to improve the visualisation of bo...
|
Latest weather forecast: more clouds on the horizon. Fall 11By Peter Boogaard Drug Discovery Cloud collaboration has allowed projects of previously unimaginable scale and scope to be constructed at an unmet price/performance ratio. Widespread access to Information and Communicati...
|
Combining chemists expertise and a computer's advanced capabilities to generate good ideas. Fall 11By Dr Matthew Segall, Edmund Champness, Dr Chris Leeding, Dr Ryan Lilien, Dr Ramgopal Mettu and Dr Brian Stevens Drug One of the defining challenges of drug discovery is the need to make complex decisions regarding the design and selection of potential drug molecules based on a relative scarcity of exper...
|
Selecting a LIMS for next-generation sequencing research. Summer 11By Bruce Pharr and Dr Michael Kuzyk Genomics has revolutionised the life sciences industry by combining human ingenuity with right-place/right-time serendipity. Advances in computer processing and storage have provided the ...
|
|
|
